Occupational Benzene Exposure and the Risk of Lymphoma Subtypes: A Meta-analysis of Cohort Studies Incorporating Three Study Quality Dimensions

Jelle Vlaanderen, Qing Lan, Hans Kromhout, Nathaniel Rothman, and Roel Vermeulen

BACKGROUND: The use of occupational cohort studies to assess the association of benzene and lymphoma is complicated by problems with exposure misclassification, outcome classification, and low statistical power.

OBJECTIVE: We performed meta-analyses of occupational cohort studies for five different lymphoma categories: Hodgkin lymphoma (HL), non-Hodgkin lymphoma (NHL), multiple myeloma (MM), acute lymphocytic leukemia (ALL), and chronic lymphocytic leukemia (CLL).

DATA EXTRACTION: We assessed three study quality dimensions to evaluate the impact of study quality variations on meta-relative risks (mRRs): stratification by the year of start of follow-up, stratification by the strength of the reported acute myelogenous leukemia association, and stratification by the quality of benzene exposure assessment.

DATA SYNTHESIS: mRRs for MM, ALL, and CLL increased with increasing study quality, regardless of the study quality dimension. mRRs for NHL also increased with increasing study quality, although this effect was less pronounced. We observed no association between occupational benzene exposure and HL.

CONCLUSIONS: Our meta-analysis provides support for an association between occupational benzene exposure and risk of MM, ALL, and CLL. The evidence for an association with NHL is less clear, but this is likely complicated by the etiologic heterogeneity of this group of diseases. Further consideration of the association between benzene and NHL will require delineation of risks by NHL subtype.

KEY WORDS: acute lymphocytic leukemia, benzene, chronic lymphocytic leukemia, Hodgkin lymphoma, leukemia, meta-analysis, multiple myeloma, non-Hodgkin lymphoma, occupational exposure. Environ Health Perspect 119:159–167 (2011). doi:10.1289/ehp.1002318 [Online 29 September 2010]

The International Agency for Research on Cancer (IARC) classified benzene as a group 1 carcinogen (carcinogenic to humans) in its 1982 and 1987 evaluations (IARC 1982, 1987) based primarily on reports of an association between occupational exposure to benzene and leukemia, particularly acute non-lymphocytic leukemia (ANLL), which consists primarily of acute myelogenous leukemia (AML). Recently, IARC updated its previous reviews of several chemicals and occupational exposure circumstances, including benzene, to reassess carcinogenicity and to consider potential associations with additional tumor sites (Baan et al. 2009). In that review, IARC determined for the first time that in addition to the confirmed association with ANLL, there was also limited evidence that benzene causes acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma (NHL), and multiple myeloma (MM) in humans (Baan et al. 2009). At the same time, in recent years, there has been a plethora of reviews and meta-analyses of benzene and one or more lymphoid neoplasms, at times reaching diametrically opposed conclusions (Alexander and Wagner 2010; Bergsgel et al. 1999; Infante 2006; Kane and Newton 2010; Lamm et al. 2005; Savitz and Andrews 1997; Schnatter et al. 2005; Smith et al. 2007; Sonoda et al. 2001; Steinmaus et al. 2008; Wong and Fu 2005; Wong and Raabe 1995, 1997, 2000a, 2000b).

There are two fundamental challenges in using the large number of occupational cohort studies that have been published over the last 30 or so years when considering the relationship between occupational benzene exposure and the risk of lymphoid neoplasms. First, there have been substantial changes in testing procedures, diagnostic criteria, and categorization of lymphoid neoplasms over the last half-century (Aisenberg 2000; Harris et al. 2000; Linet et al. 2007; Morton et al. 2007), the time period in which follow-up of these occupational cohorts took place. Indeed, diagnostic criteria that were used in these cohort studies were based on a range of classification strategies, including the International Classification of Diseases (ICD), Revisions 7–9, and ICD for Oncology, Revision 3 (ICD-O3) (World Health Organization 1955, 1965, 1975, 2000). The changing views on the categorization of lymphoid neoplasms is illustrated by the current categorization of ALL and CLL as subtypes of NHL in the most recent World Health Organization disease classification (Swerdlow et al. 2008), although these entities have been reported separately from NHL in essentially all occupational cohort studies of benzene-exposed workers. Second, there is heterogeneity in occupational cohort studies with regard to industry, sample size, documentation and level of benzene exposure, and documentation of the percentage of a given cohort that had true, nontrivial exposure to benzene. Inadequate documentation, uncertain quality of follow-up, and, most problematic, potential inclusion of “unexposed” workers in “exposed” categories would have likely resulted in attenuation of the observed associations. Further, for the purpose of reviews or meta-analyses, it can be challenging to separate informative from potentially noninformative cohorts in the face of uncertain documentation of key epidemiological study design and exposure assessment characteristics.

Given the changing nature of the diagnosis of lymphoid neoplasms over time and the heterogeneity of occupational benzene cohort study quality in the literature, it is a challenge to discern the nature of the relationship between benzene and lymphoid neoplasms. To address this issue, we developed three strategies that we employ in a set of meta-analyses of occupational cohort studies for five lymphoma categories defined according to ICD-9: Hodgkin lymphoma (HL; ICD-9 code 201), NHL (ICD-9 200, 202), MM (ICD-9 203.0), ALL (ICD-9 204.0), and CLL (ICD-9 204.1).

We applied the first strategy to assess the potential impact of the gradual increase in the quality of hematologic diagnoses over the last decades. This strategy involved stratification of the studies in the meta-analyses based on the reported start of follow-up. We used the year 1970 as a cutoff point for stratification (approximate midpoint of follow-up of all studies included in this analysis). We based the second strategy on the established strong

Address correspondence to R. Vermeulen, Institute for Risk Assessment Sciences, Division Environmental Epidemiology, Jenaalan 18d, 3584 CK, Utrecht, the Netherlands. Telephone: 31-30-2539448. Fax: 31-30-2539499. E-mail: R.C.H.Vermeulen@uu.nl

Supplemental Material is available online (doi:10.1289/ehp.1002318 via http://dx.doi.org/).

*These authors are co-senior authors.

This work was performed as part of the work package “Integrated Risk Assessment” of the Environmental Cancer Risk, Nutrition, and Individual Susceptibility Network of Excellence, operating within the European Union 6th Framework Program, Priority 5: “Food Quality and Safety” (FOOD-CT-2005-513943). The authors declare they have no actual or potential competing financial interests.

Received 20 April 2010; accepted 29 September 2010.
association between benzene and AML. We argue that any study that was not able to detect at least a suggestive association between benzene and AML most likely had serious methodologic limitations in one or more aspects of study design. Examples of possible limitations are trivial exposure to benzene in the studied cohort, inclusion of “unexposed” workers in “exposed” categories or flaws in the assessment (or categorization) of health effects (Goldstein and Shalat 2000). Therefore, we used the direction and significance level of a reported association between benzene and AML as proxies for the overall study quality (AML significance level).

We based the third strategy on the evaluation of the quality of the exposure assessment carried out in each cohort. High-quality exposure assessment is essential to discriminate exposed individuals from nonexposed individuals (Vlaanderen et al. 2008). We assigned an exposure assessment quality classification to each study based on an a priori defined classification scheme and used this classification as an additional proxy of study quality, reasoning that those cohort studies with the highest quality exposure assessment had the greatest ability to identify and include workers who were truly exposed to benzene in their analyses.

We hypothesized that application of the three study quality dimensions—stratification based on the start of follow-up, AML significance level, and exposure assessment quality—would identify a subgroup of occupational cohort studies that is most informative for the evaluation of the possible association between benzene and lymphoid neoplasms.

Materials and Methods

Study identification and data extraction. We conducted a search of PubMed (http://www.ncbi.nlm.nih.gov/sites/entrez) using the key words “benzene” and “cohort” or “case-control.” We included publications in the meta-analysis if they were published in the peer-reviewed literature, reported results for any of the five lymphoma subtypes (HL, NHL, MM, ALL, and CLL), and were conducted in the occupational setting. We checked references in all identified publications for additional studies. When more than one paper was published on the same cohort, we chose the publication with the highest quality exposure assessment [e.g., in the Australian petroleum workers cohort for AML, we chose the nested case-control study that included an elaborated exposure assessment approach (Glass et al. 2003) over a more recent update on the full cohort that included no detailed benzene exposure assessment (Gun et al. 2006)]. When multiple publications with similar quality of exposure assessment were published on the same cohort, we chose the most recent update (with the longest follow-up time). In this meta-analysis, we pooled risk ratios, odds ratios (ORs), and standardized mortality ratios (SMRs). ORs and SMRs can be interpreted as reasonable approximations of the risk ratio when the disease is rare, and these measures have been pooled with risk ratios for meta-analyses before (McElvenny et al. 2004). We use the term “relative risk” (RR) to refer to the risk ratio, the OR, or the SMR. We extracted RRAs based both on incidence and mortality. However, if a publication reported both, we chose incidence over mortality in the meta-analysis.

Risk estimates. To allow the inclusion of studies without quantitative exposure assessment in our analysis, we used only RRAs for “any occupational benzene exposure” versus “background benzene exposure” in the meta-analyses. If publications reported only RRAs stratified for cumulative exposure and not for “any occupational benzene exposure” versus “background benzene exposure,” we pooled RRAs by summing observed and expected cases for studies that reported SMRs (percentage of RRs: ALL: 4.8%; HL: 3.7%; NHL: 3.0%; MM: 3.8%; CLL: 5.6%) or by conducting a within-study random-effects meta-analysis of the nonreference exposure groups for studies that reported RRs or ORs (percentage of RRs: AML: 14.3%; NHL: 3.0%; MM: 7.7%; ALL: 5.9%; CLL: 16.7%). If publications reported only observed and expected number of cases and no RRAs, we calculated RRAs and estimated associated confidence intervals (CIs) with mid-P exact (Rothman and Boice 1979) (percentage of RRAs: AML: 4.8%; HL: 7.4%; ALL: 17.6%). For publications that reported no observed cases for any of the lymphoma subtypes, we calculated continuity corrected RRAs (observed and expected number of cases plus one) and we estimated associated CIs with mid-P exact (percentage of RRAs: ALL: 11.8%; HL: 11.1%). If studies reported zero for the lower CI, we imputed a value of 0.1 to allow estimation of the variance (percentage of RRAs: ALL: 5.9%; MM: 3.8%). Three strategies for the assessment of study quality dimensions. We stratified by the year of start of follow-up based on the information provided in the included publications (follow-up started before 1970 vs. follow-up started in or after 1970). The median start of follow-up in the stratum with studies that started follow-up before 1970 was 1947, and the median start of follow-up in the stratum with studies that started follow-up in 1970 or after was 1973.

We assigned AML significance level to each publication based on a two-sided p-value of the z-score, which we estimated by dividing the reported log RR for AML by its standard error. Based on the calculated AML significance level, we assigned one of the following categories (A–E) to each publication: A, AML RR > 1, p < 0.1; B, AML RR > 1, 0.1 ≤ p < 0.2; C, AML RR > 1, p ≥ 0.2; D, AML RR ≤ 1; E, no AML RR reported.

We assigned quality of exposure assessment (A–D) to each publication as follows: A, in the publication explicit quantitative exposure estimates for benzene were reported; B, in the publication semi-quantitative estimates of benzene exposure or quantitative estimates of exposures containing benzene (e.g., gasoline) were reported; C, in the publication some industrial hygiene sampling results to indicate that benzene exposure was present in the cohort that was studied were reported; D, the publication qualitatively indicated that benzene exposure was present in the cohort.

Statistical analyses. We conducted random-effects meta-analyses to pool the RRAs reported in the included publications. We used an α of 0.05 to assess whether meta-relative risks (mRRs) were significantly elevated. We conducted the first set of meta-analyses on the full set of studies stratified for the start of follow-up (follow-up started before 1970 vs. follow-up started in or after 1970). We compared mRRs by strata using a test of interaction as suggested by Altman and Bland (2003).

We applied the study quality dimensions of AML significance level and quality of exposure assessment in two series of meta-analyses. The initial analysis in each series included all studies regardless of quality. In each subsequent analysis, we excluded the group of studies with the lowest AML significance level or the lowest quality of exposure assessment.

We used Cochrane’s Q-test to assess between study heterogeneity in all meta-analyses. A p-value < 0.1 was considered to be statistically significant evidence for between study heterogeneity. We used F to describe the percentage of total variation across studies that was due to heterogeneity rather than chance (Higgins et al. 2003). For analyses that displayed significant between study heterogeneity, we assessed the sensitivity of the outcome of the meta-analysis for individual studies by excluding studies one at the time (jackknife analysis). We assessed publication bias with Egger’s graphical test (Egger et al. 1997). We performed all meta-analyses in Stata (version 11; StataCorp LP, College Station, TX, USA).

Results

We identified 44 publications that provided an RR for at least one of the lymphoma subtype–specific meta-analyses. We did not extract data from three publications: one study with likely underascertainment of cancer deaths as the result of the inability to identify the type of cancer for a number of cancer deaths (Infante 2005; Sorahan et al. 2005); one study for which we could not estimate the RR variance [a nested case–control study

VOLUME 119 | NUMBER 2 | February 2011 • Environmental Health Perspectives

160
that did not report CIs (Ott et al. 1989)); and one study that reported proportionate mortality ratios, which tend to underestimate the RR (Thomas et al. 1982). Table 1 lists all publications that contributed to the meta-analyses, their (assigned) cohort name, the (assigned) name of the subcohort (if relevant), the literature reference, the type of industry in which the study was performed, the follow-up period, the lymphoma subtype for which the publication was included (if reported with ICD code and revision), an indicator of whether RRs were based on incidence or mortality, the assigned AML significance level, and the assigned quality of exposure assessment. The earliest included publication dates from 1983, and the most recent publication was from 2008. For two cohorts we used non-peer-reviewed publications to extract RRs for MM (and NHL) that were not reported in the peer-reviewed publications (Atkinson et al. 2001; Delzell E, Sathikumar N, Cole P, Brill I, unpublished report). Both reports were based on the exact same methodology and follow-up time as reports of these cohorts that appeared in the peer-reviewed literature (Glass et al. 2003; Sathiakumar et al. 1995).

We included an RR for MM from a study by Decoufle et al. (1983) based on additional information that was reported in the preamble to the final Occupational Safety and Health Administration (OSHA) benzene standard of 1987 (OSHA 1987). We extracted NHL

---

**Table 1. Overview of publications included in the meta-analyses.**

| Cohort                              | Subcohort                  | Reference                  | Industry                  | Follow-up period | Included for outcomes (ICD*) | ICD revision* | AML significance level | Exposure assessment quality |
|-------------------------------------|----------------------------|----------------------------|---------------------------|------------------|-------------------------------|---------------|-----------------------|-----------------------------|
| Australian petroleum workers cohort |                            | Atkinson et al. 2001†      | Petroleum industry        | 1980–1998        | MM (203)                      | 9             | I                     | C                          | A                           |
| Australian petroleum workers cohort |                            | Glass et al. 2003          | Petroleum industry        | 1980–1998        | AML (205.0, 206.0, C, 204.1)  | 9             | I                     | C                          | A                           |
| Australian petroleum workers cohort |                            | Gun et al. 2006            | Petroleum industry        | 1981–1999        | ALL (203.0, 204.0, 206.0)     | 9             | I                     | C,D                         | A                           |
| Beaumont, Texas, petroleum refinery cohort |              | Wong et al. 2001a          | Petroleum industry        | 1945–1996        | ALL (204.0, 205.0, 206.0)     | 8             | M                     | C,D                         | A                           |
| Canadian petroleum company cohort   |                            | Schmattet al. 1996         | Petroleum industry        | 1964–1983        | MM (203), 200.2, 201, 202.2, 202.9 | 8             | M                     | E                          | A                           |
| Canadian petroleum company cohort   |                            | Lewis et al. 2003          | Petroleum industry        | 1964–1994        | AML (204), 205.0, C, 204.1, 201 | 9             | B                     | M                          | A                           |
| Caprolactam workers                |                            | Sveen et al. 2005          | Chemical industry         | 1951–2001        | MM (31, 201)                  | 8             | B                     | M,D                         | A                           |
| Conoco chemical plant cohort       |                            | Decoufle et al. 1983       | Chemical industry         | 1947–1977        | MM (*)                      | 8             | M                     | E,D                         | A                           |
| Dow cohort                         |                            | Bloemen et al. 2004        | Chemical industry         | 1940–1996        | AML (205.0, 206.0, 207.0, C, 204.1, 201) | 9             | M                     | B,D                         | A                           |
| Exxon cohort Louisiana             |                            | Huebner et al. 2004        | Petroleum industry        | 1970–1997        | ALL (204.0), 205.0, 206.0, 207.2, C, 204.1, 201 | 9             | M                     | B,D                         | A                           |
| Exxon cohort Texas                 |                            | Huebner et al. 2004        | Petroleum industry        | 1970–1997        | ALL (204.0), 205.0, 206.0, 207.0, C, 204.1, 201 | 9             | M                     | D                          | A                           |
| Finnish oil refinery workers       |                            | Pukkala 1998               | Petroleum industry        | 1967–1994        | NHL (*), 201                  | 8             | B                     | M,D                         | A                           |
| French gas and electric utility workers |              | Guemel et al. 2002         | Gas and electric industry | 1978–1989        | ALL (*), AML (*), C, 201      | 0             | I                     | D,D                         | B                           |
| Italian oil refinery               |                            | Consonni et al. 1999       | Petroleum industry        | 1949–1991        | NHL (200.2, 201)              | 8             | M                     | E,D                         | A                           |
| Martinez and Wilmington refinery and petrochemical plants, California | | Tsai et al. 1993          | Petroleum industry        | 1973–1989        | NHL (200.3, 201)              | 8             | M                     | E,D                         | A                           |
| Monsanto cohort                    |                            | Collins et al. 2003        | Chemical industry         | 1940–1999        | AML (205.0, 206.0, C, 204.1, 201) | 8             | M                     | A,D                         | A                           |
| NCI-CAPM                           |                            | Yin et al. 1996            | Multiple industries       | 1972–1987        | ALL (*), C, 201               | 9             | I                     | A,D                         | A                           |
| Norway upstream oil refinery       |                            | Hayes et al. 1997          | Multiple industries       | 1972–1987        | AML (205.0, 206.0, 207.0, C, 201) | 9             | I                     | A,D                         | A                           |
| Paulsboro, New Jersey, refinery (Mobil) |              | Kirkeleit et al. 2009      | Petroleum industry        | 1981–2003        | ALL (*), AML (*), C, 201, 206.0 | 7             | I                     | A,D                         | A                           |
| Petrochemical workers,              |                            | Collinswood et al. 1998    | Petroleum industry        | 1946–1967        | NHL (200.3, 201)              | 8             | M                     | E,D                         | A                           |
| Texas City, Texas                  |                            | Waxweiler et al. 1983      | Petroleum industry        | 1941–1977        | NHL (200, 201)                | 7             | M                     | E,D                         | A                           |
| Petroleum manufacturing plant, Illinois, USA (Shell) | | McCraw et al. 1985         | Petroleum industry        | 1973–1982        | ALL (*), C, 201               | 8             | M                     | A,D                         | A                           |
| Petroleum manufacturing plant, Illinois, USA (Shell) | | Honda et al. 1985          | Petroleum industry        | 1940–1989        | NHL (*), C, 201               | 9             | M                     | E,D                         | A                           |
| Petrochemical workers              |                            | Wong 1995                  | Chemical industry         | 1940–1987        | AML (C)                      | C             | M                     | A,D                         | A                           |
| Port Arthur, Texas, refinery workers |              | Rinsky et al. 2002         | Chemical industry         | 1950–1996        | NHL (C), C, 201               | C             | M                     | E,D                         | A                           |

continued next page
RRs for two studies by Wong and colleagues (Wong 1987a; Wong et al. 1993) from Wong (1998), a letter that provided results from additional analyses for these studies. Finally, there might have been a slight (nonidentifiable) overlap in the cohorts studied by Wong (1987a, 1987b) and Collins et al. (2003).

Table 2 shows the mRR based on random-effect meta-analyses for all studies and stratified by start of follow-up for AML and the five lymphoma subtypes (i.e., HL, NHL, MM, ALL, and CLL). The overall mRRs (95% CIs) for AML and ALL were significantly increased (mRR = 1.68 (1.35–2.10) and mRR = 1.44 (1.03–2.02), respectively). The overall mRR for MM and CLL were slightly but not significantly elevated, whereas the overall mRRs for HL and NHL were close to unity. Stratified analyses by start of follow-up showed higher RRs for AML, NHL, and CLL for studies with MM (203), NHL (200, 202), HL (201)

| Cohort                              | Subcohort           | Reference            | Industry                        | Follow-up period | Included for outcomes (ICD)† | ICD revision cumbersome | AML significance level | Exposure assessment quality | Exposure assessment quality |
|-------------------------------------|---------------------|----------------------|---------------------------------|------------------|-----------------------------|-------------------------|-------------------------|--------------------------|--------------------------|
| Richmond and El Segundo refineries | Dagg et al. 1992    | Petroleum industry   | 1950–1986                       | NHL (200), HL (201) | 8                           | M                       | E                      | D                       | D                       |
| Sample of U.S. refineries           | Kaplan 1988         | Petroleum industry   | 1972–1990                       | MM (*), HL (*)    | *[email]                     | I                       | M                      | E                       | D                       |
| Service station workers in Nordic countries | Lyng et al. 1997 | Service station workers | 1970–1990                       | AML (*), CLL (*), MM (203), NHL (200, 202), HL (201) | 7                        | I                       | C                      | C                       |
| Shell Deer Park refinery            | Tsai et al. 1996    | Petroleum industry   | 1948–1989                       | NHL (200), HL (201) | 8                           | M                       | E                      | D                       | D                       |
| Shell Louisiana refinery            | Tsai et al. 2003    | Petroleum industry   | 1973–1999                       | NHL (200), HL (201) | 8                           | M                       | E                      | D                       | D                       |
| Shoe workers cohort                 | Fu et al. 1996      | Shoe workers         | 1950–1990                       | MM (203), NHL (200, 202) | 9                           | M                       | E                      | D                       | D                       |
| Shoe workers cohort                 | U.K. cohort         | Shoe workers         | 1939–1991                       | MM (203), NHL (200, 202) | 9                           | M                       | E                      | D                       | D                       |
| Swedish seamen working on product or chemical tankers | Nilsson et al. 1998 | Petroleum tanker workers | 1971–1978                       | MM (203), NHL (200, 202), HL (201) | 8                           | I                       | E                      | D                       | D                       |
| Texaco crude oil workers            | Divine and Hartman 2000 | Petroleum workers     | 1946–1994                       | ALL (*), AML (*), CLL (*), MM (*), NHL (*), HL (201) | 8                           | M                       | A                      | D                       | D                       |
| Texaco mortality study              | Divine et al. 1995a | Petroleum industry   | 1947–1993                       | HL (201)          | 8                           | M                       | C                      | D                       | D                       |
| Texaco mortality study              | Divine et al. 1999b | Petroleum industry   | 1947–1993                       | ALL (*), AML (*), CLL (*), MM (*), NHL (*) | 8                           | M                       | C                      | D                       | D                       |
| Torrance, California, petroleum refinery | Wong et al. 2001b | Petroleum industry   | 1959–1997                       | ALL (204.0), AML (205.0), CLL (204.1), MM (203), NHL (200, 202), HL (*) | 8                           | M                       | D                      | D                       | D                       |
| U.K. oil distribution and oil refinery workers | Rushton 1993 | Petroleum industry   | 1950–1989                       | ALL                | A                           | M                      | D                      | D                       | D                       |
| U.K. oil distribution and oil refinery workers | Rushton 1993 | Petroleum industry   | 1950–1989                       | ALL                | A                           | M                      | C                      | D                       | D                       |
| U.K. oil distribution and oil refinery workers | Rushton and Romaniu 1997 | Petroleum industry | 1950–1993                       | AML (*), CLL (*) | 9                           | M                       | A                      | A                       | A                       |
| U.K. oil distribution and oil refinery workers | Sorahan 2007 | Petroleum industry   | 1951–2003                       | MM (203), NHL (200, 202), HL (201) | 9                           | M                       | E                      | D                       | D                       |
| Union Oil Company cohort            | Delzell et al. 1992 | Petroleum industry   | 1976–1990                       | MM (203), NHL (200, 202) | 9                           | M                       | A                      | D                       | D                       |
| Union Oil Company cohort            | Delzell et al. 1993 | Petroleum industry   | 1976–1990                       | MM (203), NHL (200, 202) | 9                           | M                       | E                      | D                       | D                       |
| Union Oil Company cohort            | Delzell et al. 1992 | Petroleum industry   | 1976–1990                       | AML (*)          | 9                           | M                       | A                      | D                       | D                       |
| U.S. chemical workers               | Sathiakumar et al. 1995 | Petroleum industry | 1967–1990                       | AML (*)          | 9                           | M                       | A                      | D                       | D                       |
| U.S. chemical workers               | Wong 1987a          | Chemical industry    | 1946–1977                       | HL (201)          | 8                           | M                       | E                      | A                       | A                       |
| U.S. chemical workers               | Wong 1987b          | Chemical industry    | 1946–1977                       | MM (200)          | 8                           | M                       | E                      | A                       | A                       |
| U.S. chemical workers               | Wong 1998           | Chemical industry    | 1946–1977                       | NHL (200, 202)    | 8                           | M                       | E                      | A                       | A                       |
| U.S. gasoline distribution employees | Wong et al. 1993 Land based and marine | Petroleum industry | 1946–1996                       | ALL (*), AML (*), CLL (*) | 8                           | M                       | D                      | B                       | B                       |
| U.S. gasoline distribution employees | Wong et al. 1993 Marine | Petroleum industry | 1946–1996                       | ALL (*), AML (*), CLL (*) | 8                           | M                       | D                      | B                       | B                       |

**NCI-CAPM, National Cancer Institute–Chinese Academy of Preventive Medicine.**

†, ICD revision or specific ICD code was not reported. ¶, deaths were coded according to a system developed by Statistics Netherlands (CBS); B, deaths were coded according to National Institute for Occupational Safety and Health life-table analysis system death categories; C, deaths were coded according to the ICD in effect at time of death. ¶, incidence; M, mortality. ¶, AML RR > 1, p < 0.1; B, AML RR > 1, 0.1 ≤ p < 0.2; C, AML RR > 1, p ≥ 0.2, D, AML RR < 1, E, AML RR not reported. ¶, quantitative exposure estimates for benzene; B, semiquantitative estimates of benzene exposure or quantitative estimates of exposures containing benzene; C, some industrial hygiene sampling results; D, qualitative indication that benzene exposure had occurred. ¶, Non-peer-reviewed publication.
reported an RR for AML (A–D) are largely similar to the mRRs based on all the studies (A–E). These studies therefore provide a relatively unbiased representation of the full set of studies. All outcomes except HL demonstrated an increase in mRRs with increasing AML significance level. However, the 95% CIs successively widened as a result of the reduced number of studies/RRs that were retained with each increase in AML significance level.

The increase in mRR was most pronounced for MM and ALL, and somewhat weaker for NHL and CLL. In contrast, the mRR for HL dropped with increasing AML significance level. We observed significant between-study heterogeneity for NHL and CLL in the subset of studies with AML significance level A (p < 0.10) [see Supplemental Material, Figure 2 (doi:10.1289/ehp.1002318)]. Jackknife analysis eliminating one study at the time demonstrated that, in the NHL analysis of the studies with AML significance level A, the RRs from Divine and Hartman (2000) and Dezelj et al. (unpublished report) had considerable impact on the observed between-study heterogeneity. Exclusion of both RRs from this analysis resulted in a slight decrease in the mRR (95% CI) from 1.16 (0.77–1.76) to 1.12 (0.77–1.61), with an I² (an estimate of the percentage of total variation across studies that was due to heterogeneity rather than chance) of 22.8% (p < 0.27). In the CLL analysis of the studies with AML significance level A, the RRs provided by Divine and Hartman (2000) and Rushston and Romaniuk (1997) appeared to be primarily responsible for the observed between-study heterogeneity. Exclusion of both RRs from the meta-analysis resulted in a slight decrease in the mRR from 1.39 (0.65–2.96) to 1.26 (0.65–2.43), with an I² of 0% (p = 0.94).

Table 4 shows mRRs based on random-effects meta-analyses and stratified by quality of exposure assessment. mRRs for NHL, MM, and CLL increased with increasing quality of exposure assessment. The increase in mRR was most pronounced for MM and CLL. Forest plots for AML and the five lymphoma subtypes for all studies with quality of exposure categories A and B (A, quantitative exposure estimates for benzene; B, semiquantitative estimates of benzene exposure or quantitative estimates of exposures containing benzene) are shown in the Supplemental Material, Figure 3 (doi:10.1289/ehp.1002318). Jackknife analysis eliminating one study at the time demonstrated that in the set of studies with quality of exposure categories A and B, the RRs provided by Wong et al. (1993) (land-based cohort) and Rushston and Romaniuk (1997) had considerable impact on the observed between-study heterogeneity in the CLL analysis. Exclusion of both RRs from the meta-analysis resulted in a slight decrease in the mRR (95% CI) from 1.54 (0.72–3.31) to 1.46 (0.79–2.72), with an I² of 0% (p = 0.43). The RR provided by Wong (1998) (gasoline distribution employees) had a considerable impact on the observed between study heterogeneity in the NHL analysis of the set of studies in quality of exposure categories A and B. Exclusion of this RR resulted in a slight increase in the mRR from 1.04 (0.63–1.72) to 1.27 (0.90–1.79), with an I² of 0% (p = 0.78).

Cross-stratification of AML significance level and quality of exposure assessment with the stratification based on the start of follow-up, although limited by a loss of statistical power, showed that mRR patterns with increasing AML significance level and quality of exposure assessment [see Supplemental Material, Tables 1, 2 (doi:10.1289/ehp.1002318)] were generally consistent with the patterns observed when meta-analyses were stratified by start of follow-up (Table 2).
Egger’s test revealed no significant evidence for publication bias in the data available for AML, HL, NHL, ALL, or CLL [see Supplemental Material, Figure 4 (doi: 10.1289/ehp.1002318)]. We observed evidence for bias for MM (p = 0.03), but Egger’s test became nonsignificant after exclusion of all quality of exposure assessment studies in category D (p = 0.72).

**Discussion**

We conducted a series of meta-analyses on occupational cohort studies to assess the possible association between benzene and lymphoid neoplasms. Using different dimensions of study quality, we report evidence for an association between occupational benzene exposure and lymphoma subtypes MM, ALL, and CLL. For these subtypes, mRRs increased with increasing study quality, regardless of the strategy that was used to assess study quality. mRRs for NHL also increased with increasing study quality, although this effect was less pronounced. We did not observe an association between occupational benzene exposure and HL. Importantly, with the exception of a chance finding, the increase in mRRs for NHL, MM, ALL, and CLL with increasing study quality most likely reflects an actual underlying association with at least some of these lymphoma subtypes. Because we observed mRR patterns consistent with a possible association between benzene and all lymphoma subtypes except HL, we formally explored quantitative exposure–response relations for NHL, MM, ALL, and CLL, including all studies in quality of exposure assessment category A (studies with quantitative estimates of benzene exposure) based on flexible meta-regression analyses (Vlaanderen et al. 2009). The relatively limited number of studies in category A resulted in uncertain and unstable predictions of the exposure–response curve for NHL, MM, and CLL (data not shown). For ALL, only one study in quality of exposure assessment category A was available that precluded conducting a meta-regression for this lymphoma subtype. Therefore, possible dose–response associations can only be discussed informally on a study-by-study basis.

**Assessment of study quality dimensions.**

We developed three different quality dimensions that reflect the substantial changes in diagnosis and categorization of lymphoid neoplasms over the last half century and the heterogeneity in occupational cohort studies with regard to industry, sample size, and documentation of benzene exposure. The generally higher RRs in the strata with studies that started follow-up in or after 1970 is consistent with better quality of lymphoma diagnosis in more recent years. The higher RRs are particularly noteworthy given that overall benzene exposure was likely reduced in workplaces after 1970–1980. Another secular trend in the quality of cohort studies over time was the greater use of incidence rather than mortality as end point (e.g., 91% of cohorts reporting CLL RRs with start of follow-up before 1970 used mortality as the end point vs. 43% for studies with start of follow-up in 1970 or later). It is possible that for less aggressive subtypes (e.g., CLL), subjects that died from other causes did not have lymphoma coded on their death certificate (Linet et al. 2007). However, cross-stratification of results suggested that stratification by period of follow-up explained more of the observed heterogeneity than stratification by mortality/incidence (data not shown). Although it has been suggested that the RR for leukemia subtypes observed in occupational studies might decrease with prolonged follow-up time (Richardson 2008), we found only modest evidence for this phenomenon for lymphoma subtypes. Substitution of the most recent RRs with those of previous updates did not materially change the results (data not shown).

Because the association between benzene and AML is established, we argue that a well-conducted large epidemiologic study on benzene and hematopoietic cancers should find such an association. If at least some evidence of association is not found, one could argue that there must be known or unknown methodologic limitations in the study design. Such studies would by extension most likely be noninformative regarding the association between benzene and lymphoid neoplasms. Naturally, one should realize that a failure to find evidence for an association could also be the result of insufficient statistical power. However, in our meta-analyses we observed that the strong increase in mRRs for AML with increasing AML significance levels was generally paralleled by increasing mRRs in lymphoma subtypes. In other words, studies that reported higher (and more significant) RRs for AML generally also reported higher RRs for NHL, MM, ALL, and CLL.

The quality of exposure assessment has a large impact on the ability of an epidemiologic study to identify modest increased RRs. The relevance of our quality of exposure assessment approach was illustrated with the strong increase in mRRs for AML with increasing quality of exposure assessment. This trend provides support for our assumption that studies that conducted a more detailed benzene exposure assessment likely provide higher overall quality of evidence for the potential association of benzene with adverse health outcomes. Although one would expect that the study quality indicators for AML significance level and quality of exposure assessment to be highly correlated, this is not necessarily the case. For instance, we did observe five studies in the lowest category quality of exposure assessment (D) that still reported a significant increased RR for AML, and we observed two studies from quality

**Table 4. mRRs (95% CIs) for AML and five lymphoma subtypes in cohort studies of workers exposed to benzene: stratification by exposure assessment quality.**

| Lymphoma subtype | AML significance levelb | n studies | n exposed cases | mRR |
|------------------|------------------------|-----------|----------------|-----|
| AML              | A–D (all studies)      | 21        | 217            | 1.68 (1.35–2.10)* |
|                  | A–C                    | 10        | 108            | 1.73 (1.26–2.38) |
|                  | A–B                    | 9         | 95             | 1.82 (1.25–2.66) |
|                  | A                      | 6         | 71             | 2.32 (1.55–3.47) |
| HL               | A–D (all studies)      | 27        | 146            | 0.99 (0.83–1.19) |
|                  | A–C                    | 5         | 16             | 0.99 (0.81–1.27) |
|                  | A–B                    | 4         | 6              | 0.98 (0.83–1.17) |
|                  | A                      | 4         | 6              | 0.98 (0.83–1.17) |
| NHLb             | A–D (all studies)      | 33        | 647            | 1.00 (0.89–1.13)* |
|                  | A–C                    | 8         | 106            | 1.03 (0.70–1.51)* |
|                  | A–B                    | 7         | 69             | 1.04 (0.83–1.32)* |
|                  | A                      | 6         | 50             | 1.27 (0.90–1.79) |
| MM               | A–D (all studies)      | 26        | 284            | 1.12 (0.98–1.27) |
|                  | A–C                    | 9         | 37             | 1.15 (0.74–1.79) |
|                  | A–B                    | 8         | 28             | 1.48 (0.98–2.27) |
|                  | A                      | 8         | 28             | 1.48 (0.98–2.27) |
| ALL              | A–D (all studies)      | 17        | 47             | 1.44 (1.03–2.02) |
|                  | A–C                    | 4         | 11             | 1.26 (0.5–3.16) |
|                  | A–B                    | 4         | 11             | 1.26 (0.5–3.16) |
|                  | A                      | 1         | 5              | 2.80 (0.27–29.23) |
| CLL              | A–D (all studies)      | 18        | 111            | 1.14 (0.78–1.67)* |
|                  | A–C                    | 8         | 61             | 1.38 (0.71–2.69)* |
|                  | A–B                    | 7         | 53             | 1.54 (0.72–3.31)* |
|                  | A                      | 4         | 43             | 2.44 (0.88–6.75) |

*Significant evidence for between study heterogeneity (p < 0.1).
of exposure assessment category B in the set of studies that reported an AML RR below unity (AML significance level category D). Therefore, the two study quality dimensions should be seen as complementary.

**NHL.** We observed a moderate increased RR of NHL with increasing study quality. However, neither the overall mRR nor any of the strata-specific mRRs reached formal statistical significance. Because our formal meta-regression did not result in robust dose–response associations, we qualitatively explored exposure–response relations within each exposure assessment quality category A publication that provided RRs for NHL. Of the six exposure assessment quality category A studies that reported RRs for NHL only one study reported a significant increased RR (p for trend < 0.02) with increasing cumulative exposure to benzene (Hayes et al. 1997). In contrast, in three of six publications the authors reported no clear trend of RRs for NHL with increasing cumulative exposure to benzene (Bloemen et al. 2004; Collins et al. 2003; Schnatter et al. 1996), whereas the remaining two publications did not report on the quantitative relation between NHL and cumulative exposure to benzene (Rinsky et al. 2002; Wong 1987a). In addition to these six studies, two publications that included MM in the definition of NHL did report on the quantitative relation of NHL plus MM and cumulative exposure to benzene (Glass et al. 2003; Wong 1987b). One of these studies reported an initial increase in RR with increasing exposure to benzene followed by a drop in RR in the upper cumulative exposure group (Wong 1987b), whereas the other study reported no association (Glass et al. 2003). We note, however, that a recent meta-analysis including both case–control and cohort studies reported a significant elevated mRR for NHL when we restricted the analyses to the higher exposure groups and corrected for the healthy worker (inclusion) effect (Steinmaus et al. 2008).

Overall, the epidemiologic evidence for the association between NHL and benzene is conflicting. This is illustrated by three recent meta-analyses that were based on largely the same data but reached a diametrically opposite conclusion on whether exposure to benzene is associated to NHL (Alexander and Wagner 2010; Kane and Newton 2010; Steinmaus et al. 2008). The inconsistency in findings is partly explained by study quality and failure to correct for biases but might also to a certain extent be explained by the etiologic heterogeneity within this group of diseases. If some NHL subtypes [e.g., diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma (FL)] are associated with benzene, but others are not, any NHL RR will be attenuated because of the inclusion of non-benzene-associated NHL subtypes. This is even further complicated by the fact that the distribution of NHL subtypes may vary considerably from population to population, which could lead to significant variation in reported associations between potential risk factors and total NHL (Muller et al. 2005).

A series of recent population-based case–control studies provide evidence that the association between some genetic and environmental factors varies between major NHL subtypes such as DLBCL and FL (Lan et al. 2009; Morton et al. 2008; Rothman et al. 2006; Skibola et al. 2009, 2010). Another series of recent case–control studies that used relatively high-quality retrospective exposure assessment methods have provided evidence that this might also be true for the association between benzene and NHL subtypes (Cocco et al. 2010; Miligi et al. 2006; Wong et al. 2009). The studies by Cocco et al. (2010) and Wong et al. (2009) reported a stronger association between benzene with FL [OR = 1.6 (95% CI, 0.9–2.9) and OR = 7.00 (95% CI, 1.45–33.70), respectively] than for DLBCL [OR = 0.9 (95% CI, 0.6–1.4) and OR = 0.66 (95% CI, 0.31–1.42), respectively]. The study by Miligi et al. (2006) did not report an RR for FL (due to the limited number of cases) but reported an OR of 2.4 (95% CI, 1.3–4.5) for DLBCL.

**MM.** Our analyses are supportive of an association of benzene exposure with MM. mRRs increased considerably and reached near statistical significance regardless of the study quality dimension used except for the analyses stratified by AML significance level, where formal statistical significance was reached for the two highest quality strata. Our results are similar (albeit that the point estimates of the mRRs are slightly lower) to the results from a meta-analysis by Infante (2006), in which slightly different inclusion criteria were applied (mRR = 2.13 (95% CI, 1.31–4.46)). Further evidence for an association between exposure to benzene and MM have been provided by two recent population-based case–control studies that reported increased MM RRs with increasing exposure to benzene (Cocco et al. 2010; Seniori Costantini et al. 2008). We qualitatively explored the quantitative exposure–response relation between benzene and MM. Two of eight exposure assessment quality category A studies reported an increase in RR with increasing cumulative exposure (Collins et al. 2003; Rinsky et al. 2002); in two studies the authors reported no clear trend of RRs for MM with increasing cumulative exposure to benzene (Atkinson et al. 2001; Schnatter et al. 1996); and four studies did not report on the quantitative relation between cumulative exposure to benzene and MM (Bloomen et al. 2004; Swaen et al. 2005; Wong 1987b; Yin et al. 1996). Therefore, although the evidence for an association between “any occupational benzene exposure” versus “background benzene exposure” and the RR of MM appears to be consistent, the evidence for an exposure–response relation between benzene and MM is more ambiguous. This would be explained partly by the much larger statistical power that is required to conduct quantitative exposure–response analysis, often a complication for small-scale occupational cohort studies.

**ALL.** The association between exposure to benzene and ALL is difficult to study because the disease is rare in adults (Faderl et al. 2010). It is therefore noteworthy that our analyses do strongly suggest increased RRs for ALL. We were able to identify only two population-based case–control studies that explored benzene–ALL associations in adults (Adegoke et al. 2003; Richardson et al. 1992). One case–control study reported a (nonsignificantly) increased RR for ALL with a suggestion of an exposure–response relation (Adegoke et al. 2003), whereas the other study did not observe any increased risk of ALL (Richardson et al. 1992). Together, the evidence from both cohort and case–control studies are strongly suggestive of a positive association between exposure to benzene and the RR of adult ALL. **CLL.** Our analyses suggest that exposure to benzene is associated with an increased RR for CLL. This is in line with results from four recent case–control studies that reported RRs ranging from 1.4 to 2.05 (Cocco et al. 2010; Miligi et al. 2006; Seniori Costantini et al. 2008; Wong et al. 2009). Two of these case–control studies reported an increase in RR with increasing benzene exposure (Cocco et al. 2010; Seniori Costantini et al. 2008). Of the cohort studies with quantitative exposure assessment, one study reported that the RR for the group with higher cumulative exposure was higher than the RR for the group with lower exposure (Glass et al. 2003). However, two cohort studies reported no association with cumulative exposure to benzene (Collins et al. 2003; Rushton and Romanik 1997), whereas one study did not report on the quantitative relation between cumulative exposure to benzene and CLL (Bloomen et al. 2004).

**Conclusion.** In line with the recent IARC evaluation of the carcinogenicity of benzene, our meta-analyses provide evidence for the association of occupational benzene exposure to MM, ALL, and CLL (Baan et al. 2009). Although these findings are suggestive, it is important to realize that most analyses were based on data sets of limited size. The evidence for an association between benzene and NHL (as defined in ICD-9) is less convincing, but this could be explained by the heterogeneity in the association for particular subgroups of this disease or by not accounting
for certain biases. We observed no association between benzene and HL. The discussion on the association between benzene and NHL will likely benefit from NHL subtype–specific analyses. Unfortunately, most current occupational cohort studies lack sufficient statistical power to perform such detailed analyses. Cohort studies with central pathology review and well-designed case–control studies using state-of-the-art retrospective exposure assessment methods will be needed to help evaluate the extent to which occupational benzene exposure is associated with specific subtypes of NHL.

Finally, our overall findings, taken together with the substantial experimental and molecular epidemiologic evidence that benzene exposure alters key components of the immune system relevant for lymphomagenesis (e.g., CD4+ T-cell level and CD4+ T-cell:CD8+ T-cell ratio) (Lan et al., 2004), provide support that benzene is likely to be causally related to one or more subtypes of lymphoma.

**Correction**

In the manuscript originally published online, data shown for the “AML significance level” in Table 1 differed from the correct values used in the analysis due to a sorting error. In addition, one risk estimate used in the meta-analysis for NHL was classified incorrectly as “AML significance level” C instead of as “AML significance level” E. Correction of the “AML significance level” for this risk estimate resulted in minor changes in some of the meta-relative risks reported in Table 3 and in Supplemental Material, Table 1. These errors have been corrected.

**References**

Adgeko OJ, Blair A, Shu XD, Sanderson M, Jin J, Dosemeci M, et al. 2003. Occupational history and exposure and the risk of adult leukemia in Shanghai. Ann Epidemiol 13(7):485–494.

Aisenberg AC. 2002. Historical review of lymphomas. Br J Haematol 109(3):466–476.

Alexander DD, Wagner ME. 2010. Benzene exposure and non-Hodgkin lymphoma: a meta-analysis of epidemiologic studies. J Occup Environ Med 52(2):169–189.

Altman DG, Bland JM. 1995a. Measurement error: how and why. BMJ 31(7023):852–853.

Atkinson S, Coppock J, Fritschi L, Glass DC, Gibbons C, Altman DG, Bland JM. 2003. Interaction revisited: the differences between benzene and other exposures. Occup Environ Med 60(9):676–679.

Collins JJ, Ireland B, Buckley CF, Shepperly D. 2003. Lymphohematopoietic cancer mortality among workers with benzene exposure. Occup Environ Med 60(8):576–581.

Collingwood KW, Raabe GK, Wong O. 1986. An updated cohort mortality study of workers at a northeastern United States petroleum refinery. Int Arch Occup Environ Health 68(5):277–288.

Collins JJ, Ireland B, Buckley CF, Shepperly D. 2003. Lymphohematopoietic cancer mortality among workers with benzene exposure. Occup Environ Med 60(9):676–679.

Consonni D, Pesatori AC, Tironi A, Bernucci I, Zacchetti C, Bertazzi PA. 1999. Mortality study in an Italian oil refinery: retrospective on occupational exposure and non-Hodgkin lymphoma mortality. Occup Environ Med 63(6):173–177.

Collins JJ, Hartman CM, Wendt JK. 1998a. Update of the Texaco mortality study 1947–83: Part 1. Analysis of overall patterns of mortality, research, and petrochemical workers. Occup Environ Med 55(3):167–173.

Collins JJ, Hartman CM, Wendt JK. 1999b. Update of the Texaco mortality study 1947–93: Part 2. Analysis of specific causes of death for white men employed in refining, research, and petrochemicals. Occup Environ Med 56(3):174–180.

Egger M, Davey Smith G, Schneider M, 1997. Bias in meta-analysis detected by a simple, graphical test. BMJ 315(7096):629–634.

Felder S, O’Brien S, Pui CH, Wacholder S, Travis LB, Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Egger M, Davey Smith G, Schneider M, Minder C. 1997. Bias in meta-analysis from potential outcomes. BMJ 315(7096):629–634.

Fadler S, O’Brien S, Pui CH, Wacholder S, Travis LB, Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Egger M, Davey Smith G, Schneider M, Minder C. 1997. Bias in meta-analysis from potential outcomes. BMJ 315(7096):629–634.

Hayes RB, Yin SN, Dosemeci M, Li GL, Wacholder S, Travis LB, Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Egger M, Davey Smith G, Schneider M, Minder C. 1997. Bias in meta-analysis from potential outcomes. BMJ 315(7096):629–634.

Katz AM, et al. 2003. Mortality and cancer morbidity in a historical cohort of upstream petroleum workers exposed to crude oil. Cancer Causes Control 11(1):13–23.

Lamm SH, Engel A, Byrd DM. 2005. Non-Hodgkin lymphoma and benzene exposure: the R.E.A.L. and WHO lymphoma consortium. Occup Environ Med 62(6):438–445.

Leviny E, Anttila A, Hemminki K. 1997. Organic solvents and cancer. Cancer Causes Control 8(1):406–419.

McCraw DS, Joyner RE, Cole P. 1985. Excess leukemia in a refinery population. J Occup Environ Med 27(3):220–222.

McEwen DM, Armstrong BG, Jarup L, Higgins J. 2004. Meta-analysis in occupational epidemiology: a review of practice. Occup Environ Med (51):336–344.

Migli L, Costantini A, Bergevino M, Dolev J, Bolleck J, Tumino R, et al. 2006. Occupational exposure to solvents and the risk of lymphoma. The Epidemiology Group of the International Lymphoma Epidemiology Consortium (InterLymph). Blood 110(2):995–1002.

Morton LM, Wang SS, Cozen W, Linet MS, Chatterjee N, Davis S, et al. 2008. Etiologic heterogeneity among non-Hodgkin lymphoma subtypes. Blood 112(13):5150–5160.

Muller AM, Icartor R, Mertelsmann R, Engelhardt M. 2005. Epidemiology of non-Hodgkin lymphoma (NHL): trends, geographic distribution, and etiology. Ann Hematol 84(1):1–12.

Netisson RJ, Nordlinder H, Larsson I, Gervah R. 1998. Leukemia, lymphoma, and benzene exposure in seamen on tankers. Occup Environ Med 55(9):571–572.

OSHA (Occupational Safety and Health Administration). 1987. Preamble to the Final Rule for Benzene. Washington, DC:OSHA.

Ott MG, Teta MJ, Greenhill B. 1989. Lymphatic and hematopoietic tissue cancer in a chemical manufacturing environment. Am J Ind Med 16(3):831–843.

Pukkala E. 1998. Cancer incidence among Finnish oil refinery workers, 1971–1994. J Occup Environ Med 40(8):767–779.

Richardson DB. 2008. Temporal variation in the association between benzene and leukemia mortality. Environ Health Perspect 116:370–374.

Richardson, S., Czeizler E., Bastjuji-Garin S., Lasservre E., Guenneneau C., Cadou M., et al. 1992. Occupational risk factors for acute leukemia: a case-control study. Int J Epidemiol 21(6):1063–1073.

Rinsky RA, Horning RW, Silver SR, Tseung CY. 2002. Benzene exposure and hematopoietic malignancies: a long-term epidemiologic risk assessment. Am J Ind Med 42(6):474–480.

Rothman KJ, Boice JD Jr. 1979. Epidemiologic Analysis with a Programmable Computer. Washington DC:U.S. Department of Health, Education and Welfare.

Rothman N, Skibola CF, Wang SS, Morgan G, Lan Q, Smith MT, et al. 2006. Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: a pooled analysis of 3 population-based case-control studies. Blood 112(4):264–267.

Rushton L. 1993. A 39-year follow-up of the U.K. oil refinery and benzene exposure studies. BMJ 306(6832):291–294.

Vlaanderen et al.
Rushton L, Romaniuk H. 1997. A case-control study to inves-
tigate the risk of leukaemia associated with exposure to
benzene in petroleum marketing and distribution workers
in the United Kingdom. Occup Environ Med 54(3):152–166.
Satishakumar N, Delzell E, Cole P, Brill J, Frisch J, Spivey G.
1995. A case-control study of leukemia among petroleum
workers. J Occup Environ Med 37(11):1269–1277.
Satkin KP, Wong O, Yuan LA, Bailey WJ, Newton KL, Wen CP,
et al. 1996. A 50-year mortality follow-up of a large cohort
of oil refinery workers in Texas. J Occup Environ Med
38(3):492–506.
Savitz DA, Andrews KW. 1997. Review of epidemiologic evi-
dence on benzene and lymphatic and hematopoietic can-
cers. Am J Ind Med 31(3):287–295.
Schnatter AR, Armstrong TW, Niccolich MJ, Thompson FS,
Katz AM, Huebner WW, et al. 1996. Lymphohaematopoietic
malignancies and quantitative estimates of exposure to
benzene in Canadian petroleum distribution workers.
Occup Environ Med 53(11):773–781.
Schnatter AR, Rosamilia K, Wojcik NC. 2005. Review of the
literature on benzene exposure and leukemia subtypes.
Chem Biol Interact 153–154:9–21.
Seniori Costantini A, Benvenuti A, Vineis P, Kriebel D, Tumino R,
Ramazzotti V, et al. 2008. Risk of leukemia and multiple
myeloma associated with exposure to benzene and other
organic solvents: evidence from the Italian Multicenter
case-control study, Am J Ind Med 53(11):803–811.
Skibola CF, Bracci PM, Halperin E, Conde L, Craig DW, Agana L,
et al. 2009. Genetic variants at 6p21.13 are associated
with susceptibility to follicular lymphoma. Nat Genet
41(3):343–347.
Skibola CF, Bracci PM, Nieters A, Brooks-Wilson A, de
Sanjose S, Hughes AM, et al. 2010. Tumor necrosis factor
(TNF) and lymphotoxin-alpha (LTA) polymorphisms and risk
of non-Hodgkin lymphoma in the InterLymph Consortium.
Environ Health Perspect 118:526–532.
Vlaanderen J, Portengen L, Rothman N, Lan G, Kromhout H,
Vermeulen R. 2009. Flexible meta-regression to assess the
shape of the benzene leukemia exposure response curve.
Environ Health Perspect 117:1705–1706.
Waxweiler RJ, Leftingwell SS, Haring M, Lloyd JW. 1983.
Mortality from brain tumor and other causes in a cohort
of petrochemical workers. J Natl Cancer Inst 70(1):75–81.
Waxweiler RJ, Portengen L, Rothman N, Heederik D, Kromhout H.
2008. Guidelines to evaluate human observational studies for
quantitative risk assessment. Environ Health Perspect
116:1705–1706.
Wong O, Raabe GK. 1997. Cell-type-specific leukemia analyses
in a combined cohort of more than 208,000 petroleum
workers in the United States and the United Kingdom,
1937–1989. Regul Toxicol Pharmacol 21(2):307–321.
Wong O, Raabe GK. 1995. Multiple myeloma and benzene expo-
sure in a multinational cohort of more than 250,000 petrol-
ene workers. Regul Toxicol Pharmacol 26(2):188–199.
Wong O, Raabe GK. 2000a. A critical review of cancer epidemi-
ology in the petroleum industry, with a meta-analysis of a
combined database of more than 350,000 workers. Regul
Toxicol Pharmacol 32(1):78–98.
Wong O, Raabe GK. 2000b. Non-Hodgkin’s lymphoma and expo-
sure to benzene in a multinational cohort of more than
308,000 petroleum workers, 1937 to 1996. J Occup
Environ Med 42(5):554–568.
Yin SN, Hayes RB, Linet MS, Li GL, Dosemeci M, Travis LB,
et al. 1996. A cohort study of cancer among benzene-
exposed workers in China: overall results. Am J Ind Med
29(3):227–235.
Supplemental Material

Occupational Benzene Exposure and the Risk of Lymphoma Subtypes: a Meta-Analysis of Cohort Studies Incorporating Three Study Quality Dimensions

Jelle Vlaanderen¹, Qing Lan², Hans Kromhout¹, Nathaniel Rothman²*, and Roel Vermeulen¹*

¹ Institute for Risk Assessment Sciences, Utrecht University, 3584 CK Utrecht, the Netherlands
² Division of Cancer Epidemiology and Genetics, National Cancer Institute Department of Health and Human Services, National Institutes of Health, Bethesda MD 20892, USA
* Co-senior authors
# Table of Contents

Figure 1: Forest plots of all studies for AML and five lymphoma subtypes in cohort studies of workers exposed to benzene, stratified by start of follow-up. 3

Figure 2: Forest plots of studies with *AML significance level A* for AML and five lymphoma subtypes in cohort studies of workers exposed to benzene. 9

Figure 3: Forest plots of studies with *exposure assessment quality A-B* for AML and five lymphoma subtypes in cohort studies of workers exposed to benzene. 15

Table 1 Pooled relative risks for AML and five lymphoma subtypes; stratification by start of follow-up and *AML significance level* 21

Table 2 Pooled relative risks for AML and five lymphoma subtypes; stratification by start of follow-up and *exposure assessment* 23

Figure 4: Funnel plots for AML and five lymphoma subtypes with pseudo 95% confidence limits. 24

Supplemental material, Legend funnel plots Figure 4 25

References 27
Supplemental Material, Figure 1: Forest plots of all studies for AML and five lymphoma subtypes in cohort studies of workers exposed to benzene, stratified by start of follow-up.

Sub-cohorts were identified with the following codes: Chemical workers cohort (Ch), Distribution cohort (Di), Gasoline workers cohort (Ga), Italian cohort (It), Land-based workers cohort (La), Louisiana cohort (Lo), Marine workers cohort (Ma), Oil and Gas workers cohort (Oi), Refinery cohort (Re), Texas cohort (Te), UK cohort (UK).
Sub-cohorts were identified with the following codes: Chemical workers cohort (Ch), Distribution cohort (Di), Gasoline workers cohort (Ga), Italian cohort (It), Land-based workers cohort (La), Louisiana cohort (Lo), Marine workers cohort (Ma), Oil and Gas workers cohort (Oi), Refinery cohort (Re), Texas cohort (Te), UK cohort (UK).
| Study ID | ES (95% CI) | % Weight |
|----------|-------------|----------|
| Follow-up started before 1970 |
| Bloomer2004 | 1.06 (0.51, 1.55) | 2.44 |
| Collingwood1996 | 0.46 (0.09, 1.64) | 0.14 |
| Collin2003 | 1.29 (0.68, 2.25) | 2.89 |
| Consonni1999 | 2.12 (0.88, 4.86) | 1.28 |
| Dagg1992 | 1.06 (0.63, 1.67) | 3.80 |
| Divine1996 | 0.88 (0.55, 1.41) | 7.25 |
| Divine2000 | 0.69 (0.47, 0.98) | 5.30 |
| Fu1996b(T) | 1.06 (0.71, 1.59) | 4.48 |
| Fu1996(UK) | 0.55 (0.25, 0.97) | 1.53 |
| Honda1995 | 0.89 (0.48, 1.49) | 3.30 |
| Pukkala1996 | 1.24 (0.54, 2.17) | 2.80 |
| Rinsky2002 | 0.96 (0.31, 2.25) | 4.29 |
| Sabe1996 | 0.71 (0.48, 1.01) | 2.14 |
| Schnitzer1990a | 1.19 (0.22, 6.29) | 4.49 |
| Sonnenberg2007(Di) | 1.00 (0.75, 1.31) | 6.55 |
| Sonnenberg2007(Re) | 1.14 (0.93, 1.39) | 7.88 |
| Tsai1995 | 1.22 (0.59, 2.60) | 4.45 |
| Warwel1993 | 0.69 (0.18, 2.74) | 1.01 |
| Wong1998(Ch) | 1.37 (0.55, 2.52) | 1.78 |
| Wong1998(Ga) | 0.43 (0.23, 0.80) | 3.90 |
| Wong2001a | 0.97 (0.54, 1.72) | 4.79 |
| Wong2001b | 1.21 (0.56, 2.30) | 2.25 |
| Subtotal (I-squared = 28.8%, p = 0.10) | 0.93 (0.81, 1.06) | 69.13 |
| Follow-up started in 1970 or later |
| Davito1992(Di) | 2.60 (1.20, 5.70) | 1.93 |
| Davito1992(Re) | 0.74 (0.34, 1.60) | 1.95 |
| Gu2006 | 0.89 (0.66, 1.21) | 6.36 |
| Hayes1997 | 3.00 (0.90, 9.00) | 0.88 |
| Huubner2004(Lo) | 1.47 (1.06, 2.01) | 4.99 |
| Huubner2004(Re) | 0.84 (0.47, 1.47) | 3.31 |
| Kikuchi2008 | 1.01 (0.56, 1.80) | 3.23 |
| Lyne1997 | 1.10 (0.82, 1.50) | 5.08 |
| Nilsson1998 | 3.30 (1.19, 9.00) | 1.01 |
| Tsai1995 | 0.65 (0.26, 1.59) | 0.48 |
| Tsa2003 | 2.32 (0.48, 6.79) | 0.76 |
| Subtotal (I-squared = 46.5%, p = 0.05) | 1.21 (0.94, 1.55) | 30.87 |
| Overall (I-squared = 38.0%, p = 0.02) | 1.00 (0.89, 1.13) | 100.00 |

Sub-cohorts were identified with the following codes: Chemical workers cohort (Ch), Distribution cohort (Di), Gasoline workers cohort (Ga), Italian cohort (It), Land-based workers cohort (La), Louisiana cohort (Lo), Marine workers cohort (Ma), Oil and Gas workers cohort (Oi), Refinery cohort (Re), Texas cohort (Te), UK cohort (UK).
Sub-cohorts were identified with the following codes: Chemical workers cohort (Ch), Distribution cohort (Di), Gasoline workers cohort (Ga), Italian cohort (It), Land-based workers cohort (La), Louisiana cohort (Lo), Marine workers cohort (Ma), Oil and Gas workers cohort (Og), Refinery cohort (Re), Texas cohort (Te), UK cohort (UK).
Sub-cohorts were identified with the following codes: Chemical workers cohort (Ch), Distribution cohort (Di), Gasoline workers cohort (Ga), Italian cohort (It), Land-based workers cohort (La), Louisiana cohort (Lo), Marine workers cohort (Ma), Oil and Gas workers cohort (Oi), Refinery cohort (Re), Texas cohort (Te), UK cohort (UK).
Sub-cohorts were identified with the following codes: Chemical workers cohort (Ch), Distribution cohort (Di), Gasoline workers cohort (Ga), Italian cohort (It), Land-based workers cohort (La), Louisiana cohort (Lo), Marine workers cohort (Ma), Oil and Gas workers cohort (Oi), Refinery cohort (Re), Texas cohort (Te), UK cohort (UK).
Supplemental Material, Figure 2: Forest plots of studies with AML significance level $A^a$ for AML and five lymphoma subtypes in cohort studies of workers exposed to benzene.

| Study ID          | ES (95% CI)      | Weight |
|-------------------|------------------|--------|
| Collins2003       | 2.17 (0.80, 4.82) | 7.58   |
| Divine2000        | 1.92 (1.10, 3.13) | 22.45  |
| Hayes1997         | 3.00 (1.00, 8.90) | 5.14   |
| Huebner2004(Te)   | 2.13 (1.10, 3.73) | 16.46  |
| Kirkelet2008      | 2.89 (1.25, 6.67) | 8.76   |
| Mcrav1985         | 3.94 (1.72, 7.88) | 10.60  |
| Rushton1997       | 1.86 (0.97, 3.57) | 14.46  |
| Sathiankumar1995  | 2.80 (1.10, 7.30) | 6.85   |
| Wong1995          | 5.03 (1.84, 10.97) | 7.70   |
| Overall (I-squared = 0.0%, p = 0.63) | 2.48 (1.94, 3.18) | 100.00 |

Sub-cohorts were identified with the following codes: Chemical workers cohort (Ch), Distribution cohort (Di), Gasoline workers cohort (Ga), Italian cohort (It), Land-based workers cohort (La), Louisiana cohort (Lo), Marine workers cohort (Ma), Oil and Gas workers cohort (Oi), Refinery cohort (Re), Texas cohort (Te), UK cohort (UK).

$^a$ AML RR >1, p<0.1
Sub-cohorts were identified with the following codes: Chemical workers cohort (Ch), Distribution cohort (Di), Gasoline workers cohort (Ga), Italian cohort (It), Land-based workers cohort (La), Louisiana cohort (Lo), Marine workers cohort (Ma), Oil and Gas workers cohort (Oi), Refinery cohort (Re), Texas cohort (Te), UK cohort (UK).
Sub-cohorts were identified with the following codes: Chemical workers cohort (Ch), Distribution cohort (Di), Gasoline workers cohort (Ga), Italian cohort (It), Land-based workers cohort (La), Louisiana cohort (Lo), Marine workers cohort (Ma), Oil and Gas workers cohort (Oi), Refinery cohort (Re), Texas cohort (Te), UK cohort (UK).
Sub-cohorts were identified with the following codes: Chemical workers cohort (Ch), Distribution cohort (Di), Gasoline workers cohort (Ga), Italian cohort (It), Land-based workers cohort (La), Louisiana cohort (Lo), Marine workers cohort (Ma), Oil and Gas workers cohort (Oi), Refinery cohort (Re), Texas cohort (Te), UK cohort (UK).
Sub-cohorts were identified with the following codes: Chemical workers cohort (Ch), Distribution cohort (Di), Gasoline workers cohort (Ga), Italian cohort (It), Land-based workers cohort (La), Louisiana cohort (Lo), Marine workers cohort (Ma), Oil and Gas workers cohort (Oi), Refinery cohort (Re), Texas cohort (Te), UK cohort (UK).
Sub-cohorts were identified with the following codes: Chemical workers cohort (Ch), Distribution cohort (Di), Gasoline workers cohort (Ga), Italian cohort (It), Land-based workers cohort (La), Louisiana cohort (Lo), Marine workers cohort (Ma), Oil and Gas workers cohort (Oi), Refinery cohort (Re), Texas cohort (Te), UK cohort (UK).
Supplemental Material, Figure 3: Forest plots of studies with exposure assessment quality A-B\(^a\) for AML and five lymphoma subtypes in cohort studies of workers exposed to benzene.

| Study ID         | ES (95% CI) | Weight |
|------------------|-------------|--------|
| Bloemen2004      | 1.11 (0.30, 2.83) | 9.04   |
| Collins2003      | 2.17 (0.80, 4.82)  | 12.63  |
| Glass2003        | 2.17 (0.17, 28.05) | 2.09   |
| Guene2000        | 0.70 (0.06, 7.99)  | 2.27   |
| Hayes1997        | 3.00 (1.00, 8.90)  | 9.43   |
| Ruaxton1997      | 1.86 (0.97, 3.57)  | 19.16  |
| Wong1993(La)     | 1.51 (0.80, 2.57)  | 21.59  |
| Wong1993(Ma)     | 0.74 (0.24, 1.73)  | 11.02  |
| Wong1995         | 5.03 (1.84, 10.97) | 12.78  |
| Overall (I-squared = 26.4%, p = 0.21) | 1.82 (1.25, 2.66) | 100.00 |

Sub-cohorts were identified with the following codes: Chemical workers cohort (Ch), Distribution cohort (Di), Gasoline workers cohort (Ga), Italian cohort (It), Land-based workers cohort (La), Louisiana cohort (Lo), Marine workers cohort (Ma), Oil and Gas workers cohort (Oi), Refinery cohort (Re), Texas cohort (Te), UK cohort (UK).

\(^a\) Quantitative exposure estimates for benzene (A), semi-quantitative estimates of benzene exposure or quantitative estimates of exposures containing benzene (B).
Sub-cohorts were identified with the following codes: Chemical workers cohort (Ch), Distribution cohort (Di), Gasoline workers cohort (Ga), Italian cohort (It), Land-based workers cohort (La), Louisiana cohort (Lo), Marine workers cohort (Ma), Oil and Gas workers cohort (Oi), Refinery cohort (Re), Texas cohort (Te), UK cohort (UK).
Sub-cohorts were identified with the following codes: Chemical workers cohort (Ch), Distribution cohort (Di), Gasoline workers cohort (Ga), Italian cohort (It), Land-based workers cohort (La), Louisiana cohort (Lo), Marine workers cohort (Ma), Oil and Gas workers cohort (Oi), Refinery cohort (Re), Texas cohort (Te), UK cohort (UK).
Sub-cohorts were identified with the following codes: Chemical workers cohort (Ch), Distribution cohort (Di), Gasoline workers cohort (Ga), Italian cohort (It), Land-based workers cohort (La), Louisiana cohort (Lo), Marine workers cohort (Ma), Oil and Gas workers cohort (Oi), Refinery cohort (Re), Texas cohort (Te), UK cohort (UK).
Sub-cohorts were identified with the following codes: Chemical workers cohort (Ch), Distribution cohort (Di), Gasoline workers cohort (Ga), Italian cohort (It), Land-based workers cohort (La), Louisiana cohort (Lo), Marine workers cohort (Ma), Oil and Gas workers cohort (Oi), Refinery cohort (Re), Texas cohort (Te), UK cohort (UK).
Sub-cohorts were identified with the following codes: Chemical workers cohort (Ch), Distribution cohort (Di), Gasoline workers cohort (Ga), Italian cohort (It), Land-based workers cohort (La), Louisiana cohort (Lo), Marine workers cohort (Ma), Oil and Gas workers cohort (Oi), Refinery cohort (Re), Texas cohort (Te), UK cohort (UK).
### Supplemental Material, Table 1 Pooled relative risks for AML and five lymphoma subtypes; stratification by start of follow-up and AML significance level

| Lymphoma subtype | AML significance levela | N^a | n^a | Meta relative risk (all studies) | N^b | n^b | Meta relative risk (Start follow-up before 1970) | N^c | n^c | Meta relative risk (Start follow-up 1970 and later) |
|-------------------|------------------------|-----|-----|---------------------------------|-----|-----|---------------------------------|-----|-----|---------------------------------|
| AML               | A-E (all studies)      | 21  | 217 | 1.68 (1.35-2.10)*              | 12  | 119 | 1.43 (1.07-1.92)*              | 9   | 98  | 2.08 (1.59-2.72)                |
|                   | A-D                   | 21  | 217 | 1.68 (1.35-2.10)*              | 12  | 119 | 1.43 (1.07-1.92)*              | 9   | 98  | 2.08 (1.59-2.72)                |
|                   | A-C                   | 16  | 192 | 1.88 (1.56-2.27)               | 8   | 100 | 1.72 (1.34-2.23)               | 8   | 92  | 2.11 (1.61-2.77)                |
|                   | A-B                   | 11  | 132 | 2.20 (1.77-2.72)               | 5   | 64  | 2.06 (1.47-2.89)               | 6   | 68  | 2.41 (1.77-3.29)                |
|                   | A                     | 9   | 108 | 2.48 (1.94-3.18)               | 4   | 51  | 2.29 (1.54-3.40)               | 5   | 57  | 2.88 (1.95-3.99)                |
| HL                | A-E (all studies)      | 27  | 146 | 0.99 (0.83-1.19)               | 19  | 123 | 1.01 (0.83-1.23)               | 8   | 23  | 0.91 (0.59-1.40)                |
|                   | A-D                   | 12  | 69  | 0.99 (0.77-1.27)               | 8   | 58  | 1.03 (0.78-1.36)               | 4   | 11  | 0.83 (0.47-1.48)                |
|                   | A-C                   | 9   | 39  | 0.82 (0.59-1.15)               | 5   | 28  | 0.82 (0.55-1.23)               | 4   | 11  | 0.83 (0.47-1.48)                |
|                   | A-B                   | 5   | 7   | 0.47 (0.22-0.99)               | 2   | 6   | 0.51 (0.20-1.27)               | 3   | 1^1 | 0.40 (0.11-1.44)                |
|                   | A                     | 4   | 7   | 0.50 (0.23-1.08)               | 2   | 6   | 0.51 (0.20-1.27)               | 2   | 1^1 | 0.46 (0.10-2.09)                |
| NHL               | A-E (all studies)      | 33  | 647 | 1.00 (0.89-1.13)*              | 22  | 452 | 0.93 (0.81-1.06)*              | 11  | 195 | 1.21 (0.94-1.55)*               |
|                   | A-D                   | 15  | 383 | 0.97 (0.81-1.16)*              | 8   | 208 | 0.82 (0.66-1.02)*              | 7   | 175 | 1.18 (0.91-1.53)*               |
|                   | A-C                   | 13  | 344 | 0.99 (0.81-1.21)*              | 6   | 169 | 0.81 (0.62-1.07)*              | 7   | 175 | 1.18 (0.91-1.53)*               |
|                   | A-B                   | 7   | 130 | 1.21 (0.85-1.72)*              | 2   | 40  | 0.90 (0.49-1.66)*              | 5   | 90  | 0.38 (0.26-0.56)                |
|                   | A                     | 6   | 101 | 1.16 (0.77-1.76)*              | 2   | 40  | 0.90 (0.49-1.66)*              | 4   | 61  | 1.40 (0.79-2.51)*               |
| MM                | A-E (all studies)      | 26  | 284 | 1.12 (0.98-1.27)               | 16  | 204 | 1.07 (0.93-1.24)               | 10  | 80  | 1.26 (0.92-1.71)                |
|                   | A-D                   | 14  | 160 | 1.15 (0.95-1.40)               | 7   | 105 | 1.09 (0.89-1.33)               | 7   | 55  | 1.27 (0.81-2.10)*               |
|                   | A-C                   | 12  | 137 | 1.19 (0.94-1.49)               | 5   | 92  | 1.12 (0.89-1.40)               | 7   | 55  | 1.27 (0.81-2.10)*               |
|                   | A-B                   | 7   | 69  | 1.49 (1.13-1.95)               | 2   | 29  | 1.39 (0.94-2.08)               | 5   | 40  | 1.58 (1.03-2.44)                |
|                   | A                     | 6   | 101 | 1.56 (1.11-2.21)               | 2   | 29  | 1.39 (0.94-2.08)               | 4   | 27  | 1.75 (0.94-3.26)                |
| ALL               | A-E (all studies)      | 17  | 47  | 1.44 (1.03-2.02)               | 10  | 30  | 1.30 (0.88-1.92)               | 7   | 17  | 1.92 (1.00-3.67)                |
|                   | A-D                   | 17  | 47  | 1.44 (1.03-2.02)               | 10  | 30  | 1.30 (0.88-1.92)               | 7   | 17  | 1.92 (1.00-3.67)                |
|                   | A-C                   | 11  | 29  | 1.41 (0.90-2.19)               | 5   | 15  | 1.09 (0.62-1.92)               | 6   | 14  | 2.10 (1.04-4.25)                |
|                   | A-B                   | 7   | 16  | 1.74 (0.90-3.36)               | 2   | 5   | 1.12 (0.39-3.25)               | 5   | 11  | 2.28 (0.99-5.26)                |
|                   | A                     | 5   | 12  | 1.74 (0.77-3.90)               | 1   | 3   | 1.04 (0.27-4.06)               | 4   | 9   | 2.30 (0.84-6.29)                |
| CLL               | A-E (all studies)      | 18  | 111 | 1.14 (0.78-1.67)*              | 11  | 69  | 0.87 (0.50-1.50)*              | 7   | 42  | 1.63 (1.09-2.44)                |
|                   | A-D                   | 18  | 111 | 1.14 (0.78-1.67)*              | 11  | 69  | 0.87 (0.50-1.50)*              | 7   | 42  | 1.63 (1.09-2.44)                |
|                   | A-C                   | 13  | 93  | 1.19 (0.74-1.90)*              | 7   | 55  | 0.84 (0.38-1.84)*              | 6   | 38  | 1.61 (1.00-2.59)                |
|                   | A-B                   | 8   | 57  | 1.37 (0.73-2.56)*              | 4   | 38  | 1.08 (0.29-4.06)*              | 4   | 19  | 1.84 (1.12-3.02)                |
|                   | A                     | 6   | 45  | 1.39 (0.65-2.96)*              | 3   | 36  | 1.47 (0.31-7.00)*              | 3   | 9   | 1.33 (0.64-2.76)                |

*a The term relative risk (RR) is used to refer to either the risk ratio, the odds ratio (OR), or the standardized mortality ratio (SMR).
*b AML RR >1, p<0.1 (A), AML RR >1, p<0.2 (B), AML RR >1, P>0.2 (C), AML RR reported (D), AML RR not reported (E)
**Number of studies**

**Number of exposed cases**

**NHL or Lymphosarcoma/Reticulosarcoma** (preferred NHL if the study reported both)

Two out of three studies reported null cases (continuity correction was applied in the meta-analysis)

One out of two studies reported null cases (continuity correction was applied in the meta-analysis)

* Significant evidence for between study heterogeneity (p<0.1)
Supplemental Material, Table 2 Pooled relative risks\(^a\) for AML and five lymphoma subtypes; stratification by start of follow-up and exposure assessment quality

| Lymphoma subtype | Exposure assessment quality\(^b\) | N\(^c\) | n\(^d\) | Meta relative risk (all studies) | N\(^e\) | n\(^f\) | Meta relative risk (start follow-up before 1970) | N\(^g\) | n\(^h\) | Meta relative risk (start follow-up 1970 and later) |
|------------------|----------------------------------|--------|--------|-------------------------------|--------|--------|----------------------------------|--------|--------|----------------------------------|
| AML              | A-D (all studies)                | 21     | 217    | 1.68 (1.35-2.10)*             | 12     | 119    | 1.43 (1.07-1.92)*                | 9      | 98     | 2.08 (1.59-2.72)                 |
|                  | A-C                              | 10     | 108    | 1.73 (1.26-2.38)              | 6      | 57     | 1.76 (1.11-2.79)*                | 4      | 51     | 1.60 (1.00-2.56)                 |
|                  | A-B                              | 9      | 95     | 1.82 (1.25-2.86)              | 6      | 57     | 1.76 (1.11-2.79)*                | 3      | 38     | 2.33 (0.92-5.90)                 |
|                  | A                                | 6      | 71     | 2.32 (1.55-3.47)              | 4      | 39     | 2.24 (1.28-3.95)                 | 2      | 32     | 2.65 (1.05-7.79)                 |
| HL               | A-D (all studies)                | 27     | 146    | 0.99 (0.83-1.19)              | 19     | 123    | 1.01 (0.83-1.23)                 | 8      | 23     | 0.91 (0.59-1.40)                 |
|                  | A-C                              | 5      | 16     | 0.99 (0.58-1.71)              | 4      | 6      | 0.98 (0.36-2.67)                 | 1      | 10     | 1.00 (0.53-1.90)                 |
|                  | A-B                              | 4      | 6      | 0.98 (0.36-2.67)              | 4      | 6      | 0.98 (0.36-2.67)                 | 0      | 0      | --                               |
|                  | A                                | 4      | 6      | 0.98 (0.36-2.67)              | 4      | 6      | 0.98 (0.36-2.67)                 | 0      | 0      | --                               |
| NHL*             | A-D (all studies)                | 33     | 647    | 1.00 (0.89-1.13)*             | 22     | 452    | 0.93 (0.81-1.06)*                | 11     | 195    | 1.21 (0.94-1.55)*                |
|                  | A-C                              | 8      | 106    | 1.03 (0.70-1.51)*             | 6      | 53     | 0.92 (0.57-1.49)*                | 2      | 53     | 1.51 (0.61-3.76)                 |
|                  | A-B                              | 7      | 69     | 1.04 (0.63-1.72)*             | 6      | 53     | 0.92 (0.57-1.49)*                | 1      | 16     | 3.00 (0.88-10.25)                |
|                  | A                                | 6      | 50     | 1.27 (0.90-1.79)              | 5      | 34     | 1.19 (0.83-1.69)                 | 1      | 16     | 3.00 (0.88-10.25)                |
| MM               | A-D (all studies)                | 26     | 284    | 1.12 (0.98-1.27)              | 16     | 204    | 1.07 (0.93-1.24)                 | 10     | 80     | 1.26 (0.92-1.71)                 |
|                  | A-C                              | 9      | 37     | 1.15 (0.74-1.79)              | 6      | 21     | 1.65 (1.02-2.66)                 | 3      | 16     | 0.68 (0.40-1.17)                 |
|                  | A-B                              | 8      | 28     | 1.48 (0.96-2.27)              | 6      | 21     | 1.65 (1.02-2.66)                 | 2      | 7      | 0.92 (0.34-2.47)                 |
|                  | A                                | 8      | 28     | 1.48 (0.96-2.27)              | 6      | 21     | 1.65 (1.02-2.66)                 | 2      | 7      | 0.92 (0.34-2.47)                 |
| ALL              | A-D (all studies)                | 17     | 47     | 1.44 (1.03-2.02)              | 10     | 30     | 1.30 (0.88-1.92)                 | 7      | 17     | 1.92 (1.00-3.67)                 |
|                  | A-C                              | 4      | 11     | 1.26 (0.5-3.16)               | 2      | 3      | 1.03 (0.29-3.65)                 | 2      | 8      | 1.58 (0.41-6.04)                 |
|                  | A-B                              | 4      | 11     | 1.26 (0.5-3.16)               | 2      | 3      | 1.03 (0.29-3.65)                 | 2      | 8      | 1.58 (0.41-6.04)                 |
|                  | A                                | 4      | 43     | 2.44 (0.88-6.75)              | 3      | 32     | 1.80 (0.38-8.63)*                | 1      | 11     | 3.66 (1.07-12.52)                |
| CLL              | A-D (all studies)                | 18     | 111    | 1.14 (0.71-1.67)*             | 11     | 69     | 0.87 (0.50-1.50)*                | 7      | 42     | 1.63 (1.09-2.44)                 |
|                  | A-C                              | 8      | 61     | 1.38 (0.71-2.69)*             | 5      | 38     | 1.16 (0.39-3.41)*                | 3      | 23     | 1.56 (0.62-3.97)                 |
|                  | A-B                              | 7      | 53     | 1.54 (0.72-3.31)*             | 5      | 38     | 1.16 (0.39-3.41)*                | 2      | 15     | 2.59 (1.05-6.41)                 |
|                  | A                                | 4      | 43     | 2.44 (0.88-6.75)              | 3      | 32     | 1.80 (0.38-8.63)*                | 1      | 11     | 3.66 (1.07-12.52)                |

\(^a\) The term relative risk (RR) is used to refer to either the risk ratio, the odds ratio (OR), or the standardized mortality ratio (SMR).

\(^b\) Quantitative exposure estimates for benzene (A), semi-quantitative estimates of benzene exposure or quantitative estimates of exposures containing benzene (B), some industrial hygiene sampling results (C), qualitative indication that benzene exposure had occurred (D).

\(^c\) Number of studies

\(^d\) Number of exposed cases

\(^e\) NHL or Lymphosarcoma/Reticulosarcoma (preferred NHL if the study reported both)

\(^*\) Significant evidence for between study heterogeneity (p<0.1)
Supplemental material, Figure 4: Funnel plots for AML and five lymphoma subtypes with pseudo 95% confidence limits.

Egger’s test for bias (red line) and associated p-value are included in the plots. Ids in the plot refer to the references in the legend.
### Supplemental material, Legend funnel plots Figure 4

| ID  | Reference                     | Subcohort             |
|-----|-------------------------------|-----------------------|
| 1   | (Bloemen et al. 2004)         |                       |
| 2   | (Collingwood et al. 1996)     |                       |
| 3   | (Collins et al. 2003)         |                       |
| 4   | (Consonni et al. 1999)        |                       |
| 5   | (Dagg et al. 1992)            |                       |
| 6   | (Decoufle et al. 1983)        |                       |
| 7a  | (Delzell et al. 1992)         | Oil and gas division  |
| 7b  | (Delzell et al. 1992)         | Refining division     |
| 8   | (Divine et al. 1999a)         |                       |
| 9   | (Divine et al. 1999b)         |                       |
| 10  | (Divine and Hartman 2000)     |                       |
| 11a | (Fu et al. 1996)              | Italian cohort        |
| 11b | (Fu et al. 1996)              | UK cohort             |
| 12  | (Glass et al. 2003)           |                       |
| 13  | (Atkinson et al. 2001)        |                       |
| 14  | (Guenel et al. 2002)          |                       |
| 15  | (Gun et al. 2006)             |                       |
| 16  | (Hayes et al. 1997)           |                       |
| 17  | (Honda et al. 1995)           |                       |
| 18a | (Huebner et al. 2004)         | Louisiana cohort      |
| 18b | (Huebner et al. 2004)         | Texas cohort          |
| 19  | (Kaplan 1986)                 |                       |
| 20  | (Kirkeleit et al. 2008)       |                       |
| 21  | (Lewis et al. 2003)           |                       |
| 22  | (Lynge et al. 1997)           |                       |
| 23  | (McCraw et al. 1985)          |                       |
| 24  | (Nilsson et al. 1998)         |                       |
| 25  | (Pukkala 1998)                |                       |
| 26  | (Rinsky et al. 2002)          |                       |
| 27a | (Rushton 1993)                | Refinery workers cohort|
| 27b | (Rushton 1993)                | Distribution workers cohort|
| 28  | (Rushton and Romaniuk 1997)   |                       |
| 29  | (Sathiyakumar et al. 1995)    | Oil and gas division  |
| 30  | (Satin et al. 1996)           |                       |
| 31  | (Schnatter et al. 1996)       |                       |
| 31a | (Sorahan 2007)                | Refinery workers cohort|
| 31b | (Sorahan 2007)                | Distribution workers cohort|
| 32  | (Swaen et al. 2005)           |                       |
| 33  | (Tsai et al. 1993)            |                       |
| 34  | (Tsai et al. 1996)            |                       |
| 35  | (Tsai et al. 2003)            |                       |
| 36  | (Waxweiler et al. 1983)       |                       |
| 37  | (Wong 1987a)                  |                       |
| 38  | (Wong 1987b)                  |                       |
| 39a | (Wong et al. 1993)            | Land-based workers cohort|
| 39b | (Wong et al. 1993)            | Marine workers cohort  |
40 (Wong 1995)
41a (Wong 1998) US chemical workers cohort (see Wong 1987a and Wong 1987b)
41b (Wong 1998) US gasoline distribution employees cohort (see Wong et al. 1993)
42 (Wong et al. 2001a)
43 (Wong et al. 2001b)
44 (Yin et al. 1996)
References

Atkinson S, Coppock J, Fritschi L, Glass DC, Gibbons C, Gray CN, et al. 2001. Lympho-haematopoietic Cancer and Exposure to Benzene in the Australian Petroleum Industry. Technical Report and Appendices.

Bloemen LJ, Youk A, Bradley TD, Bodner KM, Marsh G. 2004. Lympho-haematopoietic cancer risk among chemical workers exposed to benzene. Occup Environ Med 61(3):270-274.

Collingwood KW, Raabe GK, Wong O. 1996. An updated cohort mortality study of workers at a northeastern United States petroleum refinery. Int Arch Occup Environ Health 68(5):277-288.

Collins JJ, Ireland B, Buckley CF, Sheperly D. 2003. Lympho-haematopoietic cancer mortality among workers with benzene exposure. Occup Environ Med 60(9):676-679.

Consonni D, Pesatori AC, Tironi A, Bernucci I, Zocchetti C, Bertazzi PA. 1999. Mortality study in an Italian oil refinery: extension of the follow-up. Am J Ind Med 35(3):287-294.

Dagg TG, Satin KP, Bailey WJ, Wong O, Harmon LL, Swencicki RE. 1992. An updated cause specific mortality study of petroleum refinery workers. Br J Ind Med 49(3):203-212.

Decoufle P, Blattner WA, Blair A. 1983. Mortality among chemical workers exposed to benzene and other agents. Environ Res 30(1):16-25.

Delzell E, Sathiakumar N, Cole P, Brill I. 1992. A case-control study of leukemia, non hodgkin's lymphoma and multiple myeloma among employees of union oil company of california: Submitted to Union Oil Company of California.

Divine BJ, Hartman CM. 2000. Update of a study of crude oil production workers 1946-94. Occup Environ Med 57(6):411-417.

Divine BJ, Hartman CM, Wendt JK. 1999a. Update of the Texaco mortality study 1947-93: Part I. Analysis of overall patterns of mortality among refining, research, and petrochemical workers. Occup Environ Med 56(3):167-173.

---. 1999b. Update of the Texaco mortality study 1947-93: Part II. Analyses of specific causes of death for white men employed in refining, research, and petrochemicals. Occup Environ Med 56(3):174-180.

Fu H, Demers PA, Costantini AS, Winter P, Colin D, Kogevinas M, et al. 1996. Cancer mortality among shoe manufacturing workers: an analysis of two cohorts. Occup Environ Med 53(6):394-398.

Glass DC, Gray CN, Jolley DJ, Gibbons C, Sim MR, Fritschi L, et al. 2003. Leukemia risk associated with low-level benzene exposure. Epidemiology 14(5):569-577.

Guenel P, Imbernon E, Chevalier A, Crinquand-Calastreng A, Goldberg M. 2002. Leukemia in relation to occupational exposures to benzene and other agents: a case-control study nested in a cohort of gas and electric utility workers. Am J Ind Med 42(2):87-97.

Gun RT, Pratt N, Ryan P, Roder D. 2006. Update of mortality and cancer incidence in the Australian petroleum industry cohort. Occup Environ Med 63(7):476-481.

Hayes RB, Yin SN, Dosemeci M, Li GL, Wacholder S, Travis LB, et al. 1997. Benzene and the dose-related incidence of hematologic neoplasms in China. Chinese Academy of Preventive Medicine—National Cancer Institute Benzene Study Group. J Natl Cancer Inst 89(14):1065-1071.

Honda Y, Delzell E, Cole P. 1995. An updated study of mortality among workers at a petroleum manufacturing plant. J Occup Environ Med 37(2):194-200.

Huebner WW, Wojcik NC, Rosamilia K, Jorgensen G, Milano CA. 2004. Mortality updates (1970-1997) of two refinery/petrochemical plant cohorts at Baton Rouge, Louisiana, and Baytown, Texas. J Occup Environ Med 46(12):1229-1245.

Kaplan SD. 1986. Update of a mortality study of workers in petroleum refineries. J Occup Med 28(7):514-516.

Kirkkelet J, Riise T, Bratveit M, Moen BE. 2008. Increased risk of acute myelogenous leukemia and multiple myeloma in a historical cohort of upstream petroleum workers exposed to crude oil. Cancer Causes Control 19(1):13-23.

Lewis RJ, Schnatter AR, Drummond I, Murray N, Thompson FS, Katz AM, et al. 2003. Mortality and cancer morbidity in a cohort of Canadian petroleum workers. Occup Environ Med 60(12):918-928.

Lynge E, Anttila A, Hemminki K. 1997. Organic solvents and cancer. Cancer Causes Control 8(3):406-419.
McCraw DS, Joyner RE, Cole P. 1985. Excess leukemia in a refinery population. J Occup Med 27(3):220-222.

Nilsson RI, Nordlinger R, Horte LG, Jarvholm B. 1998. Leukaemia, lymphoma, and multiple myeloma in seamen on tankers. Occup Environ Med 55(8):517-521.

Pukkala E. 1998. Cancer incidence among Finnish oil refinery workers, 1971-1994. J Occup Environ Med 40(8):675-679.

Rinsky RA, Hornung RW, Silver SR, Tseng CY. 2002. Benzene exposure and hematopoietic mortality: A long-term epidemiologic risk assessment. Am J Ind Med 42(6):474-480.

Rushton L. 1993. A 39-year follow-up of the U.K. oil refinery and distribution center studies: results for kidney cancer and leukemia. Environ Health Perspect 101 Suppl 6:77-84.

Rushton L, Romaniuk H. 1997. A case-control study to investigate the risk of leukaemia associated with exposure to benzene in petroleum marketing and distribution workers in the United Kingdom. Occup Environ Med 54(3):152-166.

Sathiakumar N, Delzell E, Cole P, Brill I, Frisch J, Spivey G. 1995. A case-control study of leukemia among petroleum workers. J Occup Environ Med 37(11):1269-1277.

Satin KP, Wong O, Yuan LA, Bailey WJ, Newton KL, Wen CP, et al. 1996. A 50-year mortality follow-up of a large cohort of oil refinery workers in Texas. J Occup Environ Med 38(5):492-506.

Schnatter AR, Armstrong TW, Nicolich MJ, Thompson FS, Katz AM, Huebner WW, et al. 1996. Lymphohaematopoietic malignancies and quantitative estimates of exposure to benzene in Canadian petroleum distribution workers. Occup Environ Med 53(11):773-781.

Sorahan T. 2007. Mortality of UK oil refinery and petroleum distribution workers, 1951-2003. Occup Med (Lond) 57(3):177-185.

Swaen GM, Scheffers T, de Cock J, Slangen J, Drooge H. 2005. Leukemia risk in caprolactam workers exposed to benzene. Ann Epidemiol 15(1):21-28.

Tsai SP, Gilstrap EL, Cowles SR, Snyder PJ, Ross CE. 1993. A cohort mortality study of two California refinery and petrochemical plants. J Occup Med 35(4):415-421.

---. 1996. Long-term follow-up mortality study of petroleum refinery and chemical plant employees. Am J Ind Med 29(1):75-87.

Tsai SP, Wendt JK, Cardarelli KM, Fraser AE. 2003. A mortality and morbidity study of refinery and petrochemical employees in Louisiana. Occup Environ Med 60(9):627-633.

Waxweiler RJ, Alexander V, Leffingwell SS, Haring M, Lloyd JW. 1983. Mortality from brain tumor and other causes in a cohort of petrochemical workers. J Natl Cancer Inst 70(1):75-81.

Wong O. 1987a. An industry wide mortality study of chemical workers occupationally exposed to benzene. I. General results. Br J Ind Med 44(6):365-381.

---. 1987b. An industry wide mortality study of chemical workers occupationally exposed to benzene. II. Dose response analyses. Br J Ind Med 44(6):382-395.

---. 1995. Risk of acute myeloid leukaemia and multiple myeloma in workers exposed to benzene. Occup Environ Med 52(6):380-384.

---. 1998. Re: Benzene and the dose-related incidence of hematologic neoplasms in China. J Natl Cancer Inst 90(6):469-471.

Wong O, Harris F, Rosamiali K, Raabe GK. 2001a. An updated mortality study of workers at a petroleum refinery in Beaumont, Texas, 1945 to 1996. J Occup Environ Med 43(4):384-401.

---. 2001b. Updated mortality study of workers at a petroleum refinery in Torrance, California, 1959 to 1997. J Occup Environ Med 43(12):1089-1102.

Wong O, Harris F, Smith TJ. 1993. Health effects of gasoline exposure. II. Mortality patterns of distribution workers in the United States. Environ Health Perspect 101 Suppl 6:63-76.

Yin SN, Hayes RB, Linet MS, Li GL, Dosemeci M, Travis LB, et al. 1996. A cohort study of cancer among benzene-exposed workers in China: overall results. Am J Ind Med 29(3):227-235.
Corrected  12 November 2010

In the manuscript originally published online, data shown for the ‘AML Significance level’ in Table 1 differed from the correct values used in the analysis due to a sorting error. In addition, one risk estimate used in the meta-analysis for NHL was classified incorrectly as 'AML Significance level' C instead of as 'AML Significance level' E. Correction of the 'AML Significance level' for this risk estimate resulted in minor changes in some of the meta relative risks reported in Table 3 and in Supplemental Material, Table 1. These errors have been corrected.